Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors

11 Sept 2024

Abstract excerpt

BRCA1 is one of the most frequently-mutated tumor suppressor genes in ovarian and breast cancers. Loss of BRCA1 triggers homologous recombination (HR) repair deficiency, consequently leading to genomic instability and PARP inhibitors (PARPi)-associated synthetic lethality. Although, the roles of BRCA1 in DNA repair and replication have been extensively investigated, its tumor suppressive functions beyond genome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ferroptosis and cancer prognosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39265497
DOI: 10.1016/j.redox.2024.103350

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitorsPMID 39265497Read ↗

BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1 -Deficient CancersSemantic proximity Read ↗

FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanismSemantic proximity Read ↗

Pan-Cancer Analysis of the Role of the Ferroptosis-Related Biomarker GPX4: A Potential Target for Prognosis and ImmunotherapySemantic proximity Read ↗

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancerSemantic proximity Read ↗

Ferroptosis: the vulnerability within a cancer monsterSemantic proximity Read ↗

Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanismsSemantic proximity Read ↗

Targeting the TRIM14/USP14 axis enhances radiotherapy efficacy by inducing GPX4 degradation and disrupting ferroptotic defense in HCCSemantic proximity Read ↗

Discovery of PARP1-PROTAC as novel strategy against PARP inhibitor resistance via promoting ferroptosis in mutant-p53 triple-negative breast cancerSemantic proximity Read ↗

Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilienceSemantic proximity Read ↗

Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatinSemantic proximity Read ↗

An overview of BAP1 biological functions and current therapeutics.Semantic proximity Read ↗

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.